Approved Ligands

Pioglitazone (Actos) is a selective peroxisome proliferator-activated receptor gamma stimulator.A PPAR agonist with potential antidiabetic characteristics.

Pioglitazone (Actos) is a selective peroxisome proliferator-activated receptor gamma stimulator.A PPAR agonist with potential antidiabetic characteristics.

Pioglitazone (Actos) is a selective peroxisome proliferator-activated receptor gamma stimulator.A PPAR agonist with potential antidiabetic characteristics.

Pioglitazone (Actos) is a selective peroxisome proliferator-activated receptor gamma stimulator.A PPAR agonist with potential antidiabetic characteristics.

Pioglitazone (Actos) is a selective peroxisome proliferator-activated receptor gamma stimulator.A PPAR agonist with potential antidiabetic characteristics.

Pirenzepine.

Pitolisant (BF2.649) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Pitolisant (BF2.649) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Pitolisant (BF2.649) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Pitolisant (BF2.649) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. IC50 value: 44 nM (CXCR4): 5.7 nM (CXCL12-mediated chemotaxis) Target: CXCR4.

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.A Bcr-Abl (Bcr and c-Abl fusion), FGFR, and Flk-1 inhibitor.